Eliglustat hemitartrate
CAS No. 928659-70-5
Eliglustat hemitartrate ( Genz-112638,Eliglustat tartrate )
Catalog No. M22931 CAS No. 928659-70-5
Eliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 86 | In Stock |
|
10MG | 116 | In Stock |
|
25MG | 176 | In Stock |
|
50MG | 233 | In Stock |
|
100MG | 431 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEliglustat hemitartrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionEliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?
-
DescriptionEliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?Mice that received drug prior to significant accumulation of substrate (10 weeks of age) showed reduced levels of glucosylceramide and number of Gaucher cells in the spleen, lung and liver when compared to age-matched control animals.?Treatment of older mice that already displayed significant amounts of tissue glucosylceramide (7 months old) resulted in arrest of further accumulation of the substrate and appearance of additional Gaucher cells in affected organs.?These data indicate that substrate inhibition therapy with Genz-112638 represents a viable alternate approach to enzyme therapy to treat the visceral pathology in Gaucher disease.
-
SynonymsGenz-112638,Eliglustat tartrate
-
PathwayOthers
-
TargetOther Targets
-
Recptorglucocerebroside synthase
-
Research AreaMetabolism
-
IndicationGaucher′s Disease
Chemical Information
-
CAS Number928659-70-5
-
Formula Weight959.17
-
Molecular FormulaC50H78N4O14
-
Purity>98% (HPLC)
-
SolubilityH2O:50 mg/mL (52.13 mM);DMSO:50 mg/mL (52.13 mM)
-
SMILESCCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C(OCCO3)C3=C2)O)=O.CCCCCCCC(N[C@H](CN4CCCC4)[C@@H](C5=CC=C(OCCO6)C6=C5)O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. McEachern KA, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy ofGaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-67.
molnova catalog
related products
-
Coumarin-3-carboxyli...
The combination of Valproic acid with coumarin-3-carboxylic acid suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NF-κB signaling pathways.
-
Arundinin
Arundinin is a natural product for research related to life sciences.
-
Chamigrenal
β-Chamigrenal has anti-inflammatory activity, it has inhibitory effects on lipopolysaccharide-induced nitric oxide and prostaglandin E2 production in RAW 264.7 macrophages.